Sodium ((5-bromo-4-((4-bromonaphth-1-yl)methyl)-4H-1,2,4-triazol-3-yl)thio)methanesulfonate

ID: ALA4568207

PubChem CID: 155560602

Max Phase: Preclinical

Molecular Formula: C14H10Br2N3NaO3S2

Molecular Weight: 493.20

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  O=S(=O)([O-])CSc1nnc(Br)n1Cc1ccc(Br)c2ccccc12.[Na+]

Standard InChI:  InChI=1S/C14H11Br2N3O3S2.Na/c15-12-6-5-9(10-3-1-2-4-11(10)12)7-19-13(16)17-18-14(19)23-8-24(20,21)22;/h1-6H,7-8H2,(H,20,21,22);/q;+1/p-1

Standard InChI Key:  PRVCRALEUIWVCO-UHFFFAOYSA-M

Molfile:  

     RDKit          2D

 25 26  0  0  0  0  0  0  0  0999 V2000
   45.3335   -3.2564    0.0000 Na  0  0  0  0  0 15  0  0  0  0  0  0
   44.7103   -1.1886    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   45.1230   -1.8985    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   45.5314   -1.1862    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   43.7974   -4.3695    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   43.0840   -4.7816    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   43.0836   -5.6021    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   43.7960   -6.0116    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   44.5070   -4.7794    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   44.5096   -5.5947    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   45.2123   -5.9964    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   45.9171   -5.5879    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   45.9106   -4.7695    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   45.2032   -4.3674    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   43.7974   -3.5482    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   43.0856   -3.1396    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   42.9972   -2.3247    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   42.1938   -2.1548    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   41.7810   -2.8667    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   42.3320   -3.4739    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   43.7032   -1.9068    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   44.4188   -2.3130    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   42.1625   -4.2774    0.0000 Br  0  0  0  0  0  0  0  0  0  0  0  0
   43.7989   -6.8329    0.0000 Br  0  0  0  0  0  0  0  0  0  0  0  0
   45.8341   -2.3028    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  3  2  2  0
  4  3  2  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8 10  1  0
  9  5  1  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14  9  2  0
  5 15  1  0
 15 16  1  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 20 16  1  0
 17 21  1  0
 21 22  1  0
 20 23  1  0
  8 24  1  0
 22  3  1  0
  3 25  1  0
M  CHG  2   1   1  25  -1
M  END

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 493.20

Molecular Weight (Monoisotopic): 490.8609

AlogP: 3.94

#Rotatable Bonds: 5

Polar Surface Area: 85.08

Molecular Species: ACID

HBA: 6

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: -1.75

CX Basic pKa: ┄

CX LogP: 2.73

CX LogD: 1.27

Aromatic Rings: 3

Heavy Atoms: 24

QED Weighted: 0.43

Np Likeness Score: -1.21

References

1. Wu JW, Yin L, Liu YQ, Zhang H, Xie YF, Wang RL, Zhao GL..  (2019)  Synthesis, biological evaluation and 3D-QSAR studies of 1,2,4-triazole-5-substituted carboxylic acid bioisosteres as uric acid transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia associated with gout.,  29  (3): [PMID:30579795] [10.1016/j.bmcl.2018.12.036]

Source

Source(1):

• Scientific Literature